The role of endogenous neurotensin in psychostimulant-induced disruption of prepulse inhibition and locomotion

Schizophrenia Research

Volumn 136, Issue 1-3, 2012, Pages 88-95

  Cáceda, Ricardo ^a   Binder, Elisabeth B ^a,b   Kinkead, Becky ^a   Nemeroff, Charles B ^a,c  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Apomorphine; C fos; D amphetamine; Dizocilpine; Locomotion; Neurotensin; Prepulse inhibition

Indexed keywords

2 [5 (2,6 DIMETHOXYPHENYL) 1 [4 [N (3 DIMETHYLAMINOPROPYL) N METHYLCARBAMOYL] 2 ISOPROPYLPHENYL] 1H PYRAZOL 3 YLCARBONYLAMINO]ADAMANTANE 2 CARBOXYLIC ACID; AMPHETAMINE; DIZOCILPINE; DOPAMINE RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROTENSIN; PSYCHOSTIMULANT AGENT;

ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; CONTROLLED STUDY; DOSE RESPONSE; GENE EXPRESSION REGULATION; HYPERACTIVITY; LOCOMOTION; MALE; NEUROMODULATION; NONHUMAN; NUCLEUS ACCUMBENS; ONCOGENE C FOS; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; STARTLE REFLEX; STIMULUS RESPONSE; SUBICULUM;

ACOUSTIC STIMULATION; ADAMANTANE; AMPHETAMINE; ANALYSIS OF VARIANCE; ANIMALS; APOMORPHINE; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; GAIT DISORDERS, NEUROLOGIC; GENE EXPRESSION REGULATION; IMIDAZOLES; MALE; NEUROTENSIN; PROTO-ONCOGENE PROTEINS C-FOS; PSYCHOMOTOR PERFORMANCE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, NEUROTENSIN; RNA, MESSENGER; STARTLE REACTION;

EID: 84858000137     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2011.10.013     Document Type: Article

References (89)

1. Alonso R., Gnanadicom H., Frechin N., Fournier M., Le Fur G., Soubrie P. Blockade of neurotensin receptors suppresses the dopamine D1/D2 synergism on immediate early gene expression in the rat brain. Eur. J. Neurosci. 1999, 11:967-974.
2. Asin K.E., Wirtshafter D., Nikkel A. Amphetamine induces Fos-like immunoreactivity in the striatum of primates. Brain Res. 1996, 719:138-142.
3. Bauco P., Rompre P.P. Central neurotensin receptor activation produces differential behavioral responses in Fischer and Lewis rats. Psychopharmacology 2003, 168:253-261.
4. Bean A.J., During M.J., Roth R.H. Effects of dopamine autoreceptor stimulation on the release of colocalized transmitters: in vivo release of dopamine and neurotensin from rat prefrontal cortex. Neurosci. Lett. 1990, 108:143-148.
5. Betancur C., Cabrera R., de Kloet E.R., Pélaprat D., Rostène W. Role of endogenous neurotensin in the behavioral and neuroendocrine effects of cocaine. Neuropsychopharmacology 1998, 19:322-332.
6. Beurrier C., Malenka R.C. Enhanced inhibition of synaptic transmission by dopamine in the nucleus accumbens during behavioral sensitization to cocaine. J. Neurosci. 2002, 22:5817-5822.
7. Binder E.B., Kinkead B., Owens M.J., Kilts C.D., Nemeroff C.B. Enhanced neurotensin neurotransmission is involved in the clinically relevant behavioral effects of antipsychotic drugs: evidence from animal models of sensorimotor gating. J. Neurosci. 2001, 21:601-608.
8. Binder E.B., Kinkead B., Owens M.O., Nemeroff C.B. Neurotensin and dopamine interactions. Pharmacol. Rev. 2001, 53:453-486.
9. Binder E.B., Kinkead B., Owens M.J., Nemeroff C.B. Neurotensin receptor antagonist SR 142948A alters Fos expression and extrapyramidal side effect profile of typical and atypical antipsychotic drugs. Neuropsychopharmacology 2004, 29:2200-2207.
10. Boules M., Warrington L., Fauq A., McCormick D., Richelson E. A novel neurotensin analog blocks cocaine- and d-amphetamine-induced hyperactivity. Eur. J. Pharmacol. 2001, 426:73-76.
11. Boules M., Shaw A., Fredrickson P., Richelson E. Neurotensin agonists: potential in the treatment of schizophrenia. CNS Drugs 2007, 21:13-23.
12. Boules M., Liang Y., Briody S., Miura T., Fauq I., et al. NT79: a novel neurotensin analog with selective behavioral effects. Brain Res. 2010, 1308:35-46.
13. Bozas E., Tritos N., Phillipidis H., Stylianopoulou F. At least three neurotransmitter systems mediate a stress-induced increase in c-fos mRNA in different rat brain areas. Cell. Mol. Neurobiol. 1997, 17:157-169.
14. Brady A.M., O'Donnell P. Dopaminergic modulation of prefrontal cortical input to nucleus accumbens neurons in vivo. J. Neurosci. 2004, 24:1040-1049.
15. Cáceda R., Kinkead B., Owens M.J., Nemeroff C.B. Virally mediated increase in neurotensin 1 receptor in the nucleus accumbens decreases the behavioral effects of mesolimbic system activation by amphetamine and dizocilpine. J. Neurosci. 2005, 110:1-7.
16. Cáceda R., Kinkead B., Owen M.J., Nemeroff C.B. Neurotensin role in psychiatric and neurological diseases. Peptides 2006, 27:2385-2404.
17. Carlsson A. The neurochemical circuitry of schizophrenia. Pharmacopsychiatry 2006, 39(Suppl 1):S10-S14.
18. Carraway R.E., Leeman S.E. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J. Biol. Chem. 1973, 248:6854-6861.
19. Casti P., Marchese G., Casu G., Ruiu S., Pani L. Blockade of neurotensin receptors affects differently hypo-locomotion and catalepsy induced by haloperidol in mice. Neuropharmacology 2004, 47:128-135.
20. Cole A.J., Bhat R.V., Patt C., Worley P.F., Baraban J.M. D1 dopamine receptor activation of multiple transcription factor genes in rat striatum. J. Neurochem. 1992, 58:1420-1426.
21. Costa F.G., Frussa-Filho R., Felicio L.F. The neurotensin receptor antagonist, SR48692, attenuates the expression of amphetamine-induced behavioural sensitisation in mice. Eur. J. Pharmacol. 2001, 428:97-103.
22. Costa F.G., Frussa-Filho R., Canteras N.S., Valera A.G., Felicio L.F. Blockade of neurotensin receptors during amphetamine discontinuation indicates individual variability. Neuropeptides 2007, 41:83-91.
23. Dalia A., Wallace L.J. Amphetamine induction of c-fos in the nucleus accumbens is not inhibited by glutamate antagonists. Brain Res. 1995, 694:299-307.
24. Dilts R.P., Helton T.E., McGinty J.F. Selective induction of Fos and FRA immunoreactivity within the mesolimbic and mesostriatal dopamine terminal fields. Synapse 1993, 13:251-263.
25. Dragunow M., Faull R.L. MK-801 induces c-fos protein in thalamic and neocortical neurons of rat brain. Neurosci. Lett. 1990, 111:39-45.
26. During M.J., Bean A.J., Roth R.H. Effects of CNS stimulants on the in vivo release of the colocalized transmitters, dopamine and neurotensin, from rat prefrontal cortex. Neurosci. Lett. 1992, 140:129-133.
27. Ervin G.N., Birkemo L.S., Nemeroff C.B., Prange A.J. Neurotensin blocks certain amphetamine-induced behaviours. Nature 1981, 291:73-76.
28. Fadel J., Dobner P.R., Deutch A.Y. The neurotensin antagonist SR 48692 attenuates haloperidol-induced striatal Fos expression in the rat. Neurosci. Lett. 2001, 303:17-20.
29. Fadel J., Dobner P.R., Deutch A.Y. Amphetamine-elicited striatal Fos expression is attenuated in neurotensin null mutant mice. Neurosci. Lett. 2006, 402:97-101.
30. Fatigati M.D., Anderson R.M., Rompré P. Effects of prefrontal cortex microinjection of neurotensin-(8-13) on midbrain dopamine and non-dopamine cell firing. Brain Res. 2000, 876:196-200.
31. Feifel D., Reza T. Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating. Psychopharmacology 1999, 141:93-98.
32. Feifel D., Reza T.L. Effects of neurotensin administered into the ventral tegmental area on prepulse inhibition of startle. Behav. Brain Res. 1999, 106:189-193.
33. Feifel D., Minor K.L., Dulawa S., Swerdlow N.R. The effects of intra-accumbens neurotensin on sensorimotor gating. Brain Res. 1997, 760:80-84.
34. Feifel D., Reza T.L., Wustrow D.J., Davis M.D. Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist. J. Pharmacol. Exp. Ther. 1999, 288:710-713.
35. Feifel D., Priebe K., Shilling P.D. Startle and sensorimotor gating in rats lacking CCK-A receptors. Neuropsychopharmacology 2001, 24:663-670.
36. Feifel D., Pang Z., Shilling P.D., Melendez G., Schreiber R., Button D. Sensorimotor gating in neurotensin-1 receptor null mice. Neuropharmacology 2010, 58:173-178.
37. Fujimura M., Hashimoto K., Yamagami K. Effects of antipsychotic drugs on neurotoxicity, expression of fos-like protein and c-fos mRNA in the retrosplenial cortex after administration of dizocilpine. Eur. J. Pharmacol. 2000, 398:1-10.
38. Gao X.M., Hashimoto T., Tamminga C.A. Phencyclidine (PCP) and dizocilpine (MK801) exert time-dependent effects on the expression of immediate early genes in rat brain. Synapse 1998, 29:14-28.
39. Gass P., Spranger M., Herdegen T., Bravo R., Kock P., et al. Induction of FOS and JUN proteins after focal ischemia in the rat: differential effect of the N-methyl-d-aspartate receptor antagonist MK-801. Acta Neuropathol. 1992, 84:545-553.
40. Gass P., Herdegen T., Bravo R., Kiessling M. Induction and suppression of immediate early genes in specific rat brain regions by the non-competitive N-methyl-d-aspartate receptor antagonist MK-801. Neuroscience 1993, 53:749-758.
41. Geisler S., Zahm D.S. Neurotensin afferents of the ventral tegmental area in the rat: [1] re-examination of their origins and [2] responses to acute psychostimulant and antipsychotic drug administration. Eur. J. Neurosci. 2006, 24:116-134.
42. Grimond-Billa S.K., Norman C., G W.B., Cassaday H.J. Selectively increased trace conditioning under the neurotensin agonist PD 149163 in an aversive procedure in which SR 142948A was without intrinsic effect. J. Psychopharmacol. 2008, 22:290-299.
43. Gully D., Jeanjean F., Poncelet M., Steinberg R., Soubrie P., et al. Neuropharmacological profile of non-peptide neurotensin antagonists. Fundam. Clin. Pharmacol. 1995, 9:513-521.
44. Gully D., Labeeuw B., Boigegrain R., Oury-Donat F., Bachy A., et al. Biochemical and pharmacological activities of SR 142948A, a new potent neurotensin receptor antagonist. J. Pharmacol. Exp. Ther. 1997, 280:802-812.
45. Hanson G.R., Midgley L.P., Bush L.G., Gibb J.W. Response of extrapyramidal and limbic neurotensin systems to phencyclidine treatment. Eur. J. Pharmacol. 1995, 278:167-173.
46. Harvey J., Lacey M.G. A postsynaptic interaction between dopamine D1 and NMDA receptors promotes presynaptic inhibition in the rat nucleus accumbens via adenosine release. J. Neurosci. 1997, 17:5271-5280.
47. Hertel P., Byskov L., Didriksen M., Arnt J. Induction of tolerance to the suppressant effect of the neurotensin analogue NT69L on amphetamine-induced hyperactivity. Eur. J. Pharmacol. 2001, 422:77-81.
48. Hjelmstad G.O. Dopamine excites nucleus accumbens neurons through the differential modulation of glutamate and GABA release. J. Neurosci. 2004, 24:8621-8628.
49. Jaber M., Cador M., Dumartin B., Normand E., Stinus L., Bloch B. Acute and chronic amphetamine treatments differently regulate neuropeptide messenger RNA levels and Fos immunoreactivity in rat striatal neurons. Neuroscience 1995, 65:1041-1050.
50. Kalivas P.W., Nemeroff C.B., Prange A.J. Neuroanatomical site specific modulation of spontaneous motor activity by neurotensin. Eur. J. Pharmacol. 1982, 78:471-474.
51. Kalivas P.W., Burgess S.K., Nemeroff C.B., Prange A.J. Behavioral and neurochemical effects of neurotensin microinjection into the ventral tegmental area of the rat. Neuroscience 1983, 8:495-505.
52. Kalivas P.W., Nemeroff C.B., Prange A.J. Neurotensin microinjection into the nucleus accumbens antagonizes dopamine-induced increase in locomotion and rearing. Neuroscience 1984, 11:919-930.
53. Kinkead, B., Dobner, P.R., Egnatashvili, V., Murray, T., Deitemeyer, N., Nemeroff, C.B., 2005. Neurotensin-deficient mice have deficits in prepulse inhibition: restoration by clozapine but not haloperidol, olanzapine or quetiapine. J. Pharmacol. Exp. Ther. 315, 256-264.
54. Koch M. The neurobiology of startle. Prog. Neurobiol. 1999, 59:107-128.
55. Letter A.A., Merchant K., Gibb J.W., Hanson G.R. Effect of methamphetamine on neurotensin concentrations in rat brain regions. J. Pharmacol. Exp. Ther. 1987, 241:443-447.
56. Li Z., Boules M., Williams K., Peris J., Richelson E. The novel neurotensin analog NT69L blocks phencyclidine (PCP)-induced increases in locomotor activity and PCP-induced increases in monoamine and amino acids levels in the medial prefrontal cortex. Brain Res. 2010, 1311:28-36.
57. Marie-Claire C., Palminteri S., Romualdi P., Noble F. Effects of the selective neurotensin antagonist SR 142948A on 3,4-methylenedioxymethamphetamine-induced behaviours in mice. Neuropharmacology 2008, 54:1107-1111.
58. Merchant K.M. c-fos antisense oligonucleotide specifically attenuates haloperidol-induced increases in neurotensin/neuromedin N mRNA expression in rat dorsal striatum. Mol. Cell. Neurosci. 1994, 5:336-344.
59. Merchant K.M., Letter A.A., Gibb J.W., Hanson G.R. Changes in the limbic neurotensin systems induced by dopaminergic drugs. Eur. J. Pharmacol. 1988, 153:1-9.
60. Merchant K.M., Hanson G.R., Dorsa D.M. Induction of neurotensin and c-fos mRNA in distinct subregions of rat neostriatum after acute methamphetamine: comparison with acute haloperidol effects. J. Pharmacol. Exp. Ther. 1994, 269:806-812.
61. Miyamoto S., Snouwaert J.N., Koller B.H., Moy S.S., Lieberman J.A., Duncan G.E. Amphetamine-induced Fos is reduced in limbic cortical regions but not in the caudate or accumbens in a genetic model of NMDA receptor hypofunction. Neuropsychopharmacology 2004, 29:2180-2188.
62. Mogenson G.J., Brudzinsky S.M., Wu M., Yang C.R., Yim C.C.Y. From motivation to action: a review of dopaminergic regulation of limbic-nucleus accumbens-ventral pallidum-pedunculopontine nucleus circuitries involved in limbic-motor integration. Limbic Motor Circuits and Neuropsychiatry 1993, 193-236. CRC Press, Boca Raton, FL. P.W. Kalivas, C.D. Barnes (Eds.).
63. Nakki R., Sharp F.R., Sagar S.M., Honkaniemi J. Effects of phencyclidine on immediate early gene expression in the brain. J. Neurosci. Res. 1996, 45:13-27.
64. Norman C., Beckett S.R., Spicer C.H., Ashton D., Langlois X., Bennett G.W. Effects of chronic infusion of neurotensin and a neurotensin NT1 selective analogue PD149163 on amphetamine-induced hyperlocomotion. J. Psychopharmacol. 2008, 22:300-307.
65. Norman C., Grimond-Billa S.K., Bennett G.W., Cassaday H.J. A neurotensin agonist and antagonist decrease and increase activity, respectively, but do not preclude discrete cue conditioning. J. Psychopharmacol. 2010, 24:373-381.
66. Nouel D., Dubuc I., Kitabgi P., Costentin J. Centrally administered [D-Trp11]neurotensin, as well as neurotensin protected from inactivation by thiorphan, modifies locomotion in rats in a biphasic manner. Peptides 1990, 11:551-555.
67. Panayi F., Colussi-Mas J., Lambas-Senas L., Renaud B., Scarna H., Berod A. Endogenous neurotensin in the ventral tegmental area contributes to amphetamine behavioral sensitization. Neuropsychopharmacology 2005, 30:871-879.
68. Panegyres P.K., Hughes J. Activation of c-fos mRNA in the brain by the kappa-opioid receptor agonist enadoline and the NMDA receptor antagonist dizocilpine. Eur. J. Pharmacol. 1997, 328:31-36.
69. Paul M.L., Currie R.W., Robertson H.A. Priming of a D1 dopamine receptor behavioural response is dissociated from striatal immediate-early gene activity. Neuroscience 1995, 66:347-359.
70. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 1986, Academic, San Diego.
71. Pennartz C.M., Groenewegen H.J., Lopes da Silva F.H. The nucleus accumbens as a complex of functionally distinct neuronal ensembles: an integration of behavioural, electrophysiological and anatomical data. Prog. Neurobiol. 1994, 42:719-761.
72. Poncelet M., Souilhac J., Gueudet C., Terranova J.P., Gully D., et al. Effects of SR 48692, a selective non-peptide neurotensin receptor antagonist, on two dopamine-dependent behavioural responses in mice and rats. Psychopharmacology 1994, 116:237-241.
73. Robledo P., Maldonado R., Koob G.F. Neurotensin injected into the nucleus accumbens blocks the psychostimulant effects of cocaine but does not attenuate cocaine self-administration in the rat. Brain Res. 1993, 622:105-112.
74. Schwienbacher I., Fendt M., Hauber W., Koch M. Dopamine D1 receptors and adenosine A1 receptors in the rat nucleus accumbens regulate motor activity but not prepulse inhibition. Eur. J. Pharmacol. 2002, 444:161-169.
75. Shi W.X., Bunney B.S. Actions of neurotensin: a review of the electrophysiological studies. Ann. N. Y. Acad. Sci. 1992, 668:129-145.
76. Shilling P.D., Richelson E., Feifel D. The effects of systemic NT69L, a neurotensin agonist, on baseline and drug-disrupted prepulse inhibition. Behav. Brain Res. 2003, 143:7-14.
77. Sills T.L. Amphetamine dose dependently disrupts prepulse inhibition of the acoustic startle response in rats within a narrow time window. Brain Res. Bull. 1999, 48:445-448.
78. Simmons D.M., Arriza J.L., Swanson L.W. A complete protocol for in situ hybridization of messenger RNAs in brain and other tissues with radiolabeled single-stranded RNA probes. J. Histotechnol. 1989, 12:169-181.
79. Steinberg R., Brun P., Fournier M., Souilhac J., Rodier D., et al. SR 48692, a non-peptide neurotensin receptor antagonist differentially affects neurotensin-induced behaviour and changes in dopaminergic transmission. Neuroscience 1994, 59:921-929.
80. Swerdlow N.R., Caine S.B., Geyer M.A. Opiate-dopamine interactions in the neural substrates of acoustic startle gating in the rat. Prog. Neuropsychopharmacol. Biol. Psychiatry 1991, 15:415-426.
81. Swerdlow N.R., Geyer M.A., Braff D.L. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology 2001, 156:194-215.
82. Szakacs R., Weiczner R., Mihaly A., Krisztin-Peva B., Zador Z., Zador E. Non-competitive NMDA receptor antagonists moderate seizure-induced c-fos expression in the rat cerebral cortex. Brain Res. Bull. 2003, 59:485-493.
83. Uslaner J., Badiani A., Day H.E., Watson S.J., Akil H., Robinson T.E. Environmental context modulates the ability of cocaine and amphetamine to induce c-fos mRNA expression in the neocortex, caudate nucleus, and nucleus accumbens. Brain Res. 2001, 920:106-116.
84. Vanderschuren L.J., Kalivas P.W. Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: a critical review of preclinical studies. Psychopharmacology (Berl) 2000, 151:99-120.
85. Vita N., Oury-Donat F., Chalon P., Guillemot M., Kaghad M., et al. Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells. Eur. J. Pharmacol. 1998, 360:265-272.
86. Wagstaff J.D., Bush L.G., Gibb J.W., Hanson G.R. Endogenous neurotensin antagonizes methamphetamine-enhanced dopaminergic activity. Brain Res. 1994, 665:237-244.
87. Wagstaff J.D., Gibb J.W., Hanson G.R. Role of dopamine D1- and NMDA receptors in regulating neurotensin release in the striatum and nucleus accumbens. Brain Res. 1997, 748:241-244.
88. Wang J.Q., Smith A.J., McGinty J.F. A single injection of amphetamine or methamphetamine induces dynamic alterations in c-fos, zif/268 and preprodynorphin messenger RNA expression in rat forebrain. Neuroscience 1995, 68:83-95.
89. Wirtshafter D. A comparison of the patterns of striatal Fos-like immunoreactivity induced by various dopamine agonists in rats. Neurosci. Lett. 2000, 289:99-102.